Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial 30S ribosomal subunit – initiation factor binding interface is a specialized region on the small ribosomal subunit where the essential initiation factors IF1, IF2, and IF3 bind to coordinate the start of protein synthesis (NIH, 2023). This interface facilitates the recruitment of the initiator formyl-methionine transfer RNA (fMet-tRNA) to the ribosomal P-site and ensures the accurate selection of the mRNA start codon (Wikipedia, 2024). IF3 plays a dual role by checking the fidelity of the codon-anticodon interaction and preventing the premature association of the 50S subunit until the initiation complex is correctly formed (NIH, 2023). This site is a potent target for various antibiotics, including kasugamycin and the specialized inhibitor GE81112, which block the formation of a functional 70S ribosome (PNAS, 2011). Because the translation initiation pathway is one of the most divergent processes between bacteria and eukaryotes, targeting this interface offers high selectivity for antimicrobial therapy (NIH, 2019). Disruption of this interface effectively halts bacterial growth by preventing the synthesis of all new proteins (PatSnap, 2024). This target is particularly relevant in the context of multi-drug resistant infections, as it represents an underexploited site for novel antibiotic development (NIH, 2015).
Inhibition of translation initiation by blocking fMet-tRNA binding, interfering with start codon recognition, or preventing the assembly of the 70S ribosome.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 30S ribosomal subunit – initiation factor binding interface.